Presentation is loading. Please wait.

Presentation is loading. Please wait.

Immunohistochemistry (IHC) staining of interferon (IFN)-λ in renal tissue The figure demonstrates a repeated renal biopsy obtained from a patient after.

Published byΡεία Δουμπιώτης Modified over 5 years ago

Similar presentations

Presentation on theme: "Immunohistochemistry (IHC) staining of interferon (IFN)-λ in renal tissue The figure demonstrates a repeated renal biopsy obtained from a patient after."— Presentation transcript:

1 Immunohistochemistry (IHC) staining of interferon (IFN)-λ in renal tissue The figure demonstrates a repeated renal biopsy obtained from a patient after immunosuppressive therapy and now lupus nephritis class II. The IHC staining for IFNλ is here sparse in t... Immunohistochemistry (IHC) staining of interferon (IFN)-λ in renal tissue The figure demonstrates a repeated renal biopsy obtained from a patient after immunosuppressive therapy and now lupus nephritis class II. The IHC staining for IFNλ is here sparse in tubular cells and not expressed in the glomeruli. Original magnifications: ×20. Agneta Zickert et al. Lupus Sci Med 2016;3:e000170 ©2016 by Lupus Foundation of America

Download ppt "Immunohistochemistry (IHC) staining of interferon (IFN)-λ in renal tissue The figure demonstrates a repeated renal biopsy obtained from a patient after."

Similar presentations

Invest. Ophthalmol. Vis. Sci ;43(6): Figure Legend:

Invest. Ophthalmol. Vis. Sci ;43(6): Figure Legend:
Transthoracic needle biopsy of lung adenocarcinoma: all tumour cells are stained with 5A4 clone (anaplastic lymphoma kinase (ALK) immunohistochemistry.

Transthoracic needle biopsy of lung adenocarcinoma: all tumour cells are stained with 5A4 clone (anaplastic lymphoma kinase (ALK) immunohistochemistry.
Ann Intern Med. 2015;162(1): doi: /M Figure Legend:

Ann Intern Med. 2015;162(1): doi: /M Figure Legend:
Volume 79, Issue 11, Pages (June 2011)

Volume 79, Issue 11, Pages (June 2011)
Anifrolumab inhibits cytokine production, plasmacytoid dendritic cell (pDC) activation and the type I (interferon gene signature) IFN gene signature. Anifrolumab.

Anifrolumab inhibits cytokine production, plasmacytoid dendritic cell (pDC) activation and the type I (interferon gene signature) IFN gene signature. Anifrolumab.
Anifrolumab inhibits type I interferon (IFN)-induced IFN-stimulated response element (ISRE) signalling. Anifrolumab inhibits type I interferon (IFN)-induced.

Anifrolumab inhibits type I interferon (IFN)-induced IFN-stimulated response element (ISRE) signalling. Anifrolumab inhibits type I interferon (IFN)-induced.
Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.

Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.
Quiz Page December 2007 American Journal of Kidney Diseases

Quiz Page December 2007 American Journal of Kidney Diseases
Volume 74, Issue 1, Pages (July 2008)

Volume 74, Issue 1, Pages (July 2008)
Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.

Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.
C.-W. Tsai, V.-C. Wu, W.-C. Lin, J.-W. Huang, M.-S. Wu

C.-W. Tsai, V.-C. Wu, W.-C. Lin, J.-W. Huang, M.-S. Wu
Fig. 2. GPC3 expression in normal and tumor tissues.

Fig. 2. GPC3 expression in normal and tumor tissues.
Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor.

Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor.
Volume 70, Issue 12, Pages (December 2006)

Volume 70, Issue 12, Pages (December 2006)
EULAR Lupus Nephritis Trials Network Study Group

EULAR Lupus Nephritis Trials Network Study Group
Volume 77, Issue 9, Pages (May 2010)

Volume 77, Issue 9, Pages (May 2010)
Quiz Page December 2008 American Journal of Kidney Diseases

Quiz Page December 2008 American Journal of Kidney Diseases
Volume 75, Issue 12, Pages (June 2009)

Volume 75, Issue 12, Pages (June 2009)
Mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at the last.

Mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at the last.
Immunohistochemistry staining of interferon (IFN)-λ in renal tissue.

Immunohistochemistry staining of interferon (IFN)-λ in renal tissue.

Similar presentations

Ads by Google